Day: September 2, 2020

Allschwil, Switzerland – September 2, 2020Idorsia Ltd (SIX: IDIA) today announced the assignment and transfer of the license, collaborative development and commercialization agreement in respect to vamorolone between ReveraGen BioPharma Inc. and Idorsia in its entirety to Santhera Pharmaceuticals, whereby Santhera shall replace Idorsia as party to the ReveraGen agreement.As part of this transition, Santhera exercises the option to obtain the worldwide rights to vamorolone in Duchenne Muscular Dystrophy and all other indications from ReveraGen.In exchange for the assignment and transfer of the agreement, Idorsia will receive 366,667 shares of Santhera and an exchangeable note in the amount of CHF 10 million. Idorsia will further be entitled to development and sales milestones, as well as low single-digit percentage payments on net sales...

Allschwil, Switzerland – September 2, 2020Idorsia Ltd (SIX: IDIA) today announced the assignment and transfer of the license, collaborative development and commercialization agreement in respect to vamorolone between ReveraGen BioPharma Inc. and Idorsia in its entirety to Santhera Pharmaceuticals, whereby Santhera shall replace Idorsia as party to the ReveraGen agreement.As part of this transition, Santhera exercises the option to obtain the worldwide rights to vamorolone in Duchenne Muscular Dystrophy and all other indications from ReveraGen.In exchange for the assignment and transfer of the agreement, Idorsia will receive 366,667 shares of Santhera and an exchangeable note in the amount of CHF 10 million. Idorsia will further be entitled to development and sales milestones, as well as low single-digit percentage payments on net sales...

AUGA group, AB (hereinafter, the “Company”) published presentation of financial results for the 6 months of 2020 (see attachment), which will be presented in the Company’s investor conference webinar on the September 2 of 2020.To join the webinar, please register via following link: https://attendee.gotowebinar.com/register/3440357996802297355 . You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only a few seconds. In case plug-in cannot be downloaded, a web browser which enables attending the webinar, will open automatically. The webinar will be recorded and available online for everyone at the company’s website on http://auga.lt/en/ and on Nasdaq Baltic youtube.com account.Attachment2020HY presentation...

AUGA group, AB (toliau – „Bendrovė“) paskelbė 2020 m. šešių mėnesių finansinių rezultatų prezentaciją (pridedama), kuri bus rodoma Bendrovės internetiniame seminare š.m. rugsėjo 2 d. 9.00 val.Visus norinčius dalyvauti internetiniame seminare, prašome registruotis aktyvuojant šią nuorodą: https://attendee.gotowebinar.com/register/3440357996802297355 . Jums bus išsiųsta nuoroda prisijungti į internetinį seminarą ir instrukcija, kaip sėkmingai tai padaryti. Jungiantis į seminarą pirmą kartą, bus prašoma atsisiųsti nedidelį priedą interneto naršyklei. Internetinis seminaras bus įrašomas ir jo įrašas bus patalpintas įmonės internetiniame puslapyje www.auga.lt ir Nasdaq Baltic youtube.com paskyroje. Priedas2020H1 prezentacija LT

September 2, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:Baird Global Healthcare Conference. Fireside chat on Wednesday, September 9, 2020 at 12:15 p.m. ET.Morgan Stanley Global Healthcare Conference. Fireside chat on Monday, September 14, 2020 at 1:30 p.m. ET.BofA Global Healthcare Conference. Fireside chat on Thursday, September 17, 2020 at 10:50 a.m. BST.Stifel Immunology & Inflammation Summit. Panel on Thursday, October 1, 2020 at 11:00 a.m. ET.Additional information regarding these events will be available on the Company’s website at www.argenx.com.About argenxargenx is...

Vincit OyjLehdistötiedote 2.9.2020 kello 8:00Eka Ruola Vincit Now:n vierailevaksi johtajaksi 1.9. alkaenVincit Oyj on nimittänyt Eka Ruolan digitaaliseen liiketoimintakonsultointiin erikoistuneen Vincit Now:n interim-vetäjäksi 1.9.2020 alkaen. Ruola on ollut hasan & partners groupin pitkäaikainen toimitusjohtaja, vastaava luova johtaja ja osakas. Hän jätti keväällä yrityksen ja siirtyy Nitro Groupin pääomistajaksi kilpailukieltonsa jälkeen, keväällä 2021.Vincit Oyj:n toimitusjohtaja Mikko Kuitunen: “Olemme viime aikoina kohdanneet asiakkailtamme kasvanutta kysyntää liiketoimintakonsultointia kohtaan, erityisenä painopisteenä digitaalisen transformaation suunnittelu ja käynnistäminen. Covid19 on kiihdyttänyt kysyntää entisestään. Nyt perustettu Vincit Now tulee vastaamaan tähän tarpeeseen.”Ruola on yksi Suomen tunnetuimmista ja palkituimmista...

License gives Santhera worldwide rights to vamorolone, now also including the major markets Japan and South Korea, and paves the way for partnering in additional indicationsAgreements with Idorsia and ReveraGen give Santhera immediate control over vamorolone and defer milestone-related payments

Lizenz gibt Santhera weltweite Rechte an Vamorolone, nun auch einschliesslich der wichtigen Märkte Japan und Südkorea, und ebnet den Weg für Partnerschaften in weiteren Indikationen

This is a test from GlobeNewswire. Readers are advised to disregard.TESTING — TESTING — TESTING — TESTING — TESTING — TESTING — TESTING — TESTING –Bullet List:Bullet #1Bullet #2Bullet #3Numbered List:Item #1Item #2Item #3Nested Bullet ListBullet#1Nested Bullet 1(a)Nested Bullet 1(b)Bullet#2Bullet#3-END-Karen Yu, Director, GlobeNewswire Product Management, +1 310-258-6917; orJana Petrarca, Director, GlobeNewswire Editorial Operations, +1 708-377-1131. 

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICATORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — Allied Properties Real Estate Investment Trust (TSX:AP.UN) (“Allied”) announced today a private placement of 4,143,108 units from treasury at a price of $37.00 per unit for gross proceeds of $153.3 million. Completion of the private placement is expected to occur on or about September 4, 2020, subject to customary conditions for a transaction of this nature.Allied will use the net proceeds of the offering to fund its development program into 2021. In doing so, Allied will maintain its industry-leading debt metrics within target ranges, most importantly its net debt as a multiple of annualized adjusted EBITDA. Allied expects its development program to generate substantial amounts of new recurring...